Evaxion Biotech A/S (EVAX)
Chart Events
Performance Outlook
| Previous Close | 1.6100 |
| Open | 1.6100 |
| Bid | 1.6300 x 1100 |
| Ask | 1.6600 x 1000 |
| Day's Range | 1.6100 - 1.6784 |
| 52 Week Range | 1.4100 - 3.5200 |
| Volume | |
| Avg. Volume | 319,105 |
| Market Cap | 38.413M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- MarketWatch
Evaxion's stock soars after getting FDA approval for mid-stage cancer trial
U.S.-listed shares of Evaxion Biotech A/S jumped about 17% in premarket trading on Tuesday after the company said the Food and Drug Administration has allowed a Phase 2b clinical trial testing its experimental cancer vaccine to move forward. The study is evaluating Evaxion's EVX-01 in combination with Merck & Co. Inc.'s Keytruda as a treatment for metastatic melanoma in Australia, Europe, and the U.S. Erik Heegaard, Evaxion's chief medical officer, said the FDA's decision "is an important step t
- Benzinga
Evaxion, ExpreS2ion Ink Research Pact For Cytomegalovirus Vaccine Candidate
Evaxion Biotech A/S (NASDAQ: EVAX) has signed a Vaccine Discovery Collaboration Agreement with ExpreS2ion Biotech Holding AB for the joint development of a novel cytomegalovirus (CMV) vaccine candidate. During the discovery phase of the collaboration, Evaxion will use its proprietary AI platform, RAVEN, to design a next-generation vaccine candidate that elicits both cellular and humoral/antibody responses. The antigen constructs derived from Evaxion's AI platform will be produced by ExpreS2ion,
- Benzinga
Evaxion Biotech Highlights Promising Data From Personalized Cancer Immunotherapy
Evaxion Biotech A/S (NASDAQ: EVAX) has announced interim safety and immunogenicity data from the Phase 1/2a first-in-human study of its DNA-based cancer immunotherapy, EVX-02. In the clinical study, EVX-02 is given in combination with a checkpoint inhibitor and targets cancer mutations, neoantigens, in patients with resected melanoma. "We are thrilled to announce promising interim data from the first eight patients...All patients demonstrated a specific T-cell immune response induced by the trea
